Levi & Korsinsky notifies investors that it has commenced an investigation into Allarity Therapeutics, Inc. (NASDAQ: ALLR) concerning potential violations of the federal securities laws.
On July 22, 2024, Allarity filed a current report on Form 8-K with the SEC. The filing reveals that the Company received a "Wells Notice" from the SEC. The Company stated in its filing that, "the Wells Notice relates to the Company's disclosures regarding meetings with the United States Food and Drug Administration (the 'FDA') regarding the Company's NDA [New Drug Application] for Dovitinib or Dovitinib-DRP," and that "Allarity also understands that three of its former officers received Wells Notices from the SEC relating to the same conduct." Additionally, "the Wells Notice informed the Company that the SEC Staff has made a preliminary determination to recommend that the SEC file an enforcement action against the Company that would allege certain violations of the federal securities laws." The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
If you suffered a loss on your Allarity Therapeutics, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





